1. Home
  2. MIRM
  3. MIRM News

Latest Mirum Pharmaceuticals Inc. (MIRM) News on November 16, 2024

Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results
MIRM

Simply Wall St.

21 hours ago

Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter Results

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
MIRM

Business Wire

2 days ago

Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting

Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
MIRM

Simply Wall St.

2 days ago

Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations

MIRM

GuruFocus.com

3 days ago

Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ...

Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
MIRM

Zacks

4 days ago

Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
MIRM

Zacks

4 days ago

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates

MIRM

MT Newswires

4 days ago

Mirum Pharmaceuticals' Q3 Loss Narrows, Revenue Rises

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
MIRM

Business Wire

4 days ago

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

7 days ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
MIRM

Business Wire

9 days ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

High Growth Tech Stocks In The United States To Watch
MIRM

Simply Wall St.

10 days ago

High Growth Tech Stocks In The United States To Watch

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
MIRM

Business Wire

12 days ago

Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know
MIRM

Zacks

16 days ago

Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
MIRM

Business Wire

16 days ago

Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting

Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth
MIRM

Insider Monkey

24 days ago

Mirum Pharmaceuticals (MIRM): A Small-Cap Biotech with Strong Sales Growth

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

a month ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIRM

MT Newswires

a month ago

Mirum Pharmaceuticals Says Volixibat Gets FDA Breakthrough Therapy Designation in Cholestatic Pruritus

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
MIRM

Business Wire

a month ago

Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis

MIRM

GuruFocus.com

a month ago

Mirum Pharmaceuticals Inc (MIRM) Q2 2024 Earnings Call Highlights: Record Sales Surge and ...

Exploring High Growth Tech Stocks In The US October 2024
MIRM

Simply Wall St.

a month ago

Exploring High Growth Tech Stocks In The US October 2024

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

2 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up
MIRM

Investor's Business Daily

2 months ago

Four Biotech Stocks Rally Toward Buy Points As Funds Load Up

Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
MIRM

Zacks

2 months ago

Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?

High Growth Tech Stocks To Watch In August 2024
MIRM

Simply Wall St.

3 months ago

High Growth Tech Stocks To Watch In August 2024

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
MIRM

Business Wire

3 months ago

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

MIRM

MT Newswires

3 months ago

Evercore ISI Raises Price Target on Mirum Pharmaceuticals to $66 From $62, Keeps Outperform Rating

Mirum (MIRM) Banks on Livmarli, Overdependence a Concern
MIRM

Zacks

3 months ago

Mirum (MIRM) Banks on Livmarli, Overdependence a Concern

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
MIRM

Simply Wall St.

3 months ago

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

3 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
MIRM

Zacks

3 months ago

Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
MIRM

Zacks

3 months ago

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
MIRM

Business Wire

3 months ago

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
MIRM

Business Wire

4 months ago

Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024

Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?
MIRM

Zacks

4 months ago

Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?

MIRM

MT Newswires

4 months ago

Mirum Pharmaceuticals Gets FDA Label Expansion Approval for Liver Disease Treatment; Shares Jump

Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
MIRM

Business Wire

4 months ago

Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older

Mirum Pharmaceuticals (NASDAQ:MIRM) delivers shareholders solid 23% CAGR over 5 years, surging 11% in the last week alone
MIRM

Simply Wall St.

4 months ago

Mirum Pharmaceuticals (NASDAQ:MIRM) delivers shareholders solid 23% CAGR over 5 years, surging 11% in the last week alone

Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves
MIRM

Investor's Business Daily

4 months ago

Health Care Stocks Give IBD 50 A Boost, And These Are Making Bullish Moves

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

4 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
MIRM

Zacks

4 months ago

Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion

Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
MIRM

Zacks

4 months ago

Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why

MIRM

MT Newswires

4 months ago

Mirum Pharmaceuticals Gets Marketing Approval for Livmarli in Europe

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
MIRM

Business Wire

4 months ago

Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC

MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50
MIRM

Investor's Business Daily

5 months ago

MercadoLibre, A Few Other Growth Stocks, Among New Faces In IBD 50

MIRM

MT Newswires

5 months ago

Mirum Pharmaceuticals Submits New Drug Application for Cholesterol Metabolism Treatment

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
MIRM

Business Wire

5 months ago

Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX

Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling
MIRM

Investor's Business Daily

5 months ago

Biotech Stock Explodes On Drug Trial News As Sales Keep Doubling

MIRM

MT Newswires

5 months ago

Stifel Adjusts Mirum Pharmaceuticals Price Target to $66 From $48, Maintains Buy Rating

Mirum (MIRM) Soars on Interim Data From Liver Disease Studies
MIRM

Zacks

5 months ago

Mirum (MIRM) Soars on Interim Data From Liver Disease Studies

MIRM

MT Newswires

5 months ago

Evercore ISI Adjusts Price Target on Mirum Pharmaceuticals to $62 From $53, Maintains Outperform Rating

MIRM

MT Newswires

5 months ago

Raymond James Adjusts Price Target on Mirum Pharmaceuticals to $71 From $60, Maintains Strong Buy Rating

MIRM

MT Newswires

5 months ago

Citigroup Adjusts Price Target on Mirum Pharmaceuticals to $64 From $38, Maintains Buy Rating

MIRM

MT Newswires

5 months ago

JMP Securities Adjusts Price Target on Mirum Pharmaceuticals to $68 From $66, Maintains Market Outperform Rating

MIRM

MT Newswires

5 months ago

Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $57 From $53, Maintains Overweight Rating

MIRM

MT Newswires

5 months ago

JPMorgan Adjusts Price Target on Mirum Pharmaceuticals to $39 From $31, Maintains Overweight Rating

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?
MIRM

Zacks

5 months ago

Mirum Pharmaceuticals (MIRM) Soars 27.3%: Is Further Upside Left in the Stock?

MIRM

MT Newswires

5 months ago

Sector Update: Health Care Stocks Retreat Late Afternoon

MIRM

MT Newswires

5 months ago

Sector Update: Health Care Stocks Ease in Afternoon Trading

MIRM

MT Newswires

5 months ago

Mirum Pharmaceuticals Advances after Reporting Positive Trial Results for Prospective Cholangitis Treatment

MIRM

MT Newswires

5 months ago

Cantor Fitzgerald Adjusts Price Target on Mirum Pharmaceuticals to $50 From $45, Maintains Overweight Rating

MIRM

MT Newswires

5 months ago

Baird Adjusts Mirum Pharmaceuticals Price Target to $39 From $34, Maintains Outperform Rating

Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
MIRM

Business Wire

5 months ago

Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
MIRM

Business Wire

5 months ago

Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook
MIRM

GuruFocus.com

5 months ago

A Data-Driven Analysis of Netflix's Streaming Dominance and Future Outlook

MIRM

Energy Global

5 months ago

ANDRITZ to equip new Silvan hydropower plant in Türkiye

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings
MIRM

USA TODAY

5 months ago

Supreme Court Justice Alito talks polarization, his wife talks revenge in secret recordings

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management
MIRM

Business Wire

5 months ago

Pacer ETFs Rings in its 9th Anniversary as Firm nears $50 Billion in Assets Under Management

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins
MIRM

Business Wire

5 months ago

Indra Energy Drives Sustainability Focus through the Penguins Pledge with the Pittsburgh Penguins

SEALSQ to Launch Two New Quantum Resistant Chips
MIRM

GlobeNewswire

5 months ago

SEALSQ to Launch Two New Quantum Resistant Chips

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll
MIRM

Reuters

5 months ago

Shrinking Fed rate cut expectations to keep US Treasury yields elevated: Reuters poll

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030
MIRM

GlobeNewswire

5 months ago

Global Upstream Bioprocessing Market Analysis Report 2024-2030: A $59.24 Billion Market by 2030, Registering a CAGR of 14.3% from 2024 to 2030

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

5 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
MIRM

Zacks

5 months ago

Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress
MIRM

Business Wire

5 months ago

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC Highlighted at EASL Congress

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
MIRM

Business Wire

5 months ago

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

EMA CHMP endorses Mirum Pharmaceuticals’ LIVMARLI for PFIC
MIRM

Pharmaceutical Technology

5 months ago

EMA CHMP endorses Mirum Pharmaceuticals’ LIVMARLI for PFIC

MIRM

MT Newswires

6 months ago

Mirum Pharmaceuticals Gets Positive Opinion From EU Committee on Marketing Authorization for Livmarli to Treat PFIC

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
MIRM

Business Wire

6 months ago

Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older

Shareholders May Be More Conservative With Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) CEO Compensation For Now
MIRM

Simply Wall St.

6 months ago

Shareholders May Be More Conservative With Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) CEO Compensation For Now

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
MIRM

Business Wire

6 months ago

Long-Term Data from Mirum’s LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress

Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns
MIRM

Zacks

6 months ago

Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns

When Will Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Become Profitable?
MIRM

Simply Wall St.

6 months ago

When Will Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Become Profitable?

Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting
MIRM

Business Wire

6 months ago

Mirum Pharmaceuticals’ LIVMARLI Data Showcased at ESPGHAN Annual Meeting

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript
MIRM

Insider Monkey

6 months ago

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q1 2024 Earnings Call Transcript

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

6 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIRM

GuruFocus.com

6 months ago

Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss

MIRM

MT Newswires

6 months ago

Morgan Stanley Adjusts Price Target on Mirum Pharmaceuticals to $53 From $57, Keeps Overweight Rating

Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
MIRM

Zacks

6 months ago

Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates

MIRM

Thomson Reuters StreetEvents

6 months ago

Q1 2024 Mirum Pharmaceuticals Inc Earnings Call

MIRM

GuruFocus.com

6 months ago

Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ...

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
MIRM

Business Wire

6 months ago

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
MIRM

Business Wire

6 months ago

Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
MIRM

Business Wire

6 months ago

Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC

Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management
MIRM

Newsfile

6 months ago

Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
MIRM

Business Wire

6 months ago

Mirum Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
MIRM

Zacks

7 months ago

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
MIRM

Zacks

7 months ago

Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIRM

Business Wire

7 months ago

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
MIRM

Business Wire

7 months ago

Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome

Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
MIRM

Zacks

8 months ago

Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?

Share on Social Networks: